Braftovi is owned by Array Biopharma Inc.
Braftovi contains Encorafenib.
Braftovi has a total of 13 drug patents out of which 0 drug patents have expired.
Braftovi was authorised for market use on 27 June, 2018.
Braftovi is available in capsule;oral dosage forms.
Braftovi can be used as treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test, indicated in combination with binimetinib for the treatment of melanoma with a braf mutation, braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy, treatment of melanoma, treatment of melanoma with a braf mutation; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test, treatment of melanoma; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy, treatment of melanoma mediated by a b-raf protein kinase; braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a braf v600e mutation, as detected by an fda-approved test, after prior therapy; braftovi is a kinase inhibitor indicated in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a braf v600e or v600k mutation, as detected by an fda- approved test.
Drug patent challenges can be filed against Braftovi from 2022-06-27.
The generics of Braftovi are possible to be released after 05 August, 2033.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8946250 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Jul, 2029
(6 years from now) | |
US8541575 | ARRAY BIOPHARMA INC | 3,4-diarylpyrazoles as protein kinase inhibitors |
Feb, 2030
(6 years from now) | |
US8501758 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US9593099 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9850230 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(7 years from now) | |
US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(8 years from now) | |
US10258622 | ARRAY BIOPHARMA INC | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate |
Nov, 2032
(9 years from now) | |
US9387208 | ARRAY BIOPHARMA INC | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
US9763941 | ARRAY BIOPHARMA INC | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate |
Nov, 2032
(9 years from now) | |
US9474754 | ARRAY BIOPHARMA INC | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor |
Aug, 2033
(10 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jun 27, 2023 |
Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
New Indication (I) | Apr 8, 2023 |
Drugs and Companies using ENCORAFENIB ingredient
NCE-1 date: 2022-06-27
Market Authorisation Date: 27 June, 2018
Treatment: Treatment of melanoma with a braf mutation; Braftovi is a kinase inhibitor indicated in combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (crc) with a b...
Dosage: CAPSULE;ORAL
28
United States
9
European Union
8
Japan
6
China
5
Poland
5
Slovenia
5
Hong Kong
5
Lithuania
5
Denmark
5
Croatia
5
Hungary
5
Spain
5
EA
5
Portugal
4
Chile
4
Canada
4
Brazil
4
RS
4
Cyprus
4
Mexico
4
Australia
4
Singapore
4
Peru
3
Korea, Republic of
3
Ukraine
3
Morocco
3
Guatemala
3
Argentina
3
New Zealand
3
Colombia
3
Tunisia
3
Israel
2
ME
2
Philippines
2
Taiwan
2
India
2
Malaysia
2
San Marino
2
South Africa
2
Ecuador
2
Jordan
1
Georgia
1
Dominican Republic
1
Luxembourg
1
Costa Rica
1
Turkey
1
Netherlands
1
Honduras
1
Uruguay
1
Nicaragua
1
Norway
1
Austria
1
Cuba
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic